Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Ferring signs licensing agreement with Seikagaku for condoliase

Aug. 29, 2016

Researchers from Genentech identify novel potent and selective NIK inhibitors

Aug. 26, 2016

Hemispherx Biopharma's NDA for rintatolimod receives approval in Argentina

Aug. 24, 2016

Novel compound E-6887 shows promise for treating lupus

Aug. 24, 2016

Gilead begins phase III program for filgotinib in rheumatoid arthritis

Aug. 23, 2016

Medshine Discovery discloses JAK inhibitors

Aug. 12, 2016

MPC-300-IV shows dose-related improvements in phase II trial in biologic refractory RA

Aug. 11, 2016

Ablynx reports topline phase IIb results for vobarilizumab in patients with rheumatoid arthritis

Aug. 10, 2016

Autologous BMC is safe and effective in treating patients with atrophic non-unions

Aug. 8, 2016

Omeros' lead MASP-3 inhibitor shows efficacy in arthritis model

Aug. 5, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...